A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.

Trial Details

NCT ID

NCT06776952

Phase

PHASE3

Sponsor

Evopoint Biosciences Inc.

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

XNW5004 ; Chidamide placebo
XNW5004 placebo; Chidamide

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Aged 18-70 years (inclusive)，gender not limited.
Pathologically diagnosed, relapsed or refractory peripheral T-cell lymphoma.
Disease status defined as relapsed or refractory after \>=1 prior systemic treatment lines, and have not received treatment with HDAC inhibitors, s…
Subjects who have received prior radiotherapy are allowed to enroll, but radiotherapy alone is not considered a systemic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →